This data suggests that S100A4 is indeed a direct transcriptional target of the Wnt/β-catenin/TCF-mediated signaling pathway, strongly suggesting novel therapeutic interventions or screening for pharmacologically active compounds to reduce S100A4 expression in CRC. Here, S100A4 is linked to colorectal carcinoma.